Neoadjuvant Chemoradiotherapy (ncrt) Combined with Sequential Tislelizumab for Resectable Esophageal Squamous Cell Carcinoma (ESCC): Preliminary Results of a Single-Arm, Open-Label Phase Ib Trial (CRIS).
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined